Thyroid dysfunction during interferon alpha therapy for chronic hepatitis C: challenges in differential diagnosis and treatment

Autori

  • Rosaria Certo Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Messina, Messina
  • Giuseppe Giuffrida Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Messina, Messina
  • Alfredo Campennì Department of Biomedical and Dental Sciences, and Morpho-Functional Images, Unit of Nuclear Medicine, University of Messina, Messina<strong><br /></strong>
  • Francesco Trimarchi <p>Accademia PeloritanadeiPericolanti at the University of Messina, Messina <strong> </strong></p>
  • Rosaria Maddalena Ruggeri Accademia PeloritanadeiPericolanti at the University of Messina, Messina

DOI:

https://doi.org/10.6092/1828-6550/APMB.106.2.2018.A3

Parole chiave:

Thyroiditis, Thyroid disease, Interferon alpha, Hepatitis C, Autoimmune thyroid disease

Abstract

Recombinant interferon alpha (IFNα), alone or in combinationwith ribavirin, has been for many years the standard therapy for chronic hepatitis C. Thyroid disorders represent a quite common side-effect of such therapies, occurring in up to 15% of patients, and may pose several diagnostic and therapeutical challenges. Here we report a paradigmatical case, occurred a few years ago, of a 39-year-old man, who developed a biphasic thyroid dysfunction while receiving IFNα treatment for HCV infection

Riferimenti bibliografici

Benvenga, S., Ruggeri, R.M., Trimarchi, F. (2012). Thyroid and drugs. In: Thyroid Diseases. Monaco, F. (ed). CRC Press, Taylor & Francis Group, Boca Raton, pp 469-492.

2. Kesavachandran, C.N., Haamann, F., Nienhaus, A. (2013). Frequency of Thyroid Dysfunctions during Interferon Alpha Treatment of Single and Combination Therapy in Hepatitis C Virus-Infected Patients: A Systematic Review Based Analysis. PlosOne. 8(2):e55364. doi.org/10.1371/journal.pone.0055364.

3. Carella, C., Mazziotti, G., Amato, G., Braverman, L.E., Roti, E. (2004). Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J ClinEndocrinolMetab. 89:3656-3661

4. Mandac, J.C., Chaudhry, S., Sherman, K.E., Tomer, Y. (2006) The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology. 43:661-672.

5. Horsley Silva, J.L., Vargas, H.E. (2017) New therapies for hepatitis C virus infection. GastroenterolHepatol (NY). 13(1):22-31.

Dowloads

Pubblicato

2018-12-18

Fascicolo

V. 106 N. 2 (2018)

Sezione

CLINICAL CASE SEMINAR

Licenza

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:
  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).